Tianjin Pharmaceutical Da Ren Tang Group's strong financials hint at potential for long-term value increase despite recent stock price drop. Analysts predict continued earnings expansion due to the company's high ROE, net income growth, and efficient reinvestment.
Tianjin Pharmaceutical Da Ren Tang Group's low P/E ratio may reflect the market's pessimistic view of its future earnings growth. The weak share price, leading to a lower P/E ratio, suggests that unless the company's earnings outlook improves, the share price may remain suppressed.
Tianjin Pharmaceutical Da Ren Tang Group's commendable performance is due to reinvestment and high return rate, driving significant earnings growth, with predictions of accelerated earnings.
Tianjin Pharmaceutical Da Ren Tang Group Corporationに関するコメント
New variant of COVID-19 is soaring in Singapore. Gryphon or XBB is a fast-spreading new subvariant that is part of a 'new class' of Omicron.
MSN
$Tianjin Pharmaceutical Da Ren Tang Group Corporation (600329.SH)$ $Acesian Partners (5FW.SG)$ $Parkson Retail - watch list (O9E.SG)$
TJはUSD1.91のtpを超えました。
天津製薬大人堂グループ株式会社は、漢方薬、西洋医薬品、健康製品、医療器具を生産、販売しています。会社はまた、遺伝子関連のバイオ医薬品も製造しています。天津製薬は、Great Wall、Cypress、Healthのブランド名で製品を販売しています。グループの事業は、漢方薬、漢方飲料、漢方薬原料、バイオテクノロジー医薬品、化学原料医薬品および製剤、栄養・健康製品など、幅広い製品に及んでいます。20種類以上の製剤で800種以上の医薬品を取り揃えています。
huge difference in Shanghai and Singapore for this stock.
まだコメントはありません